WealthShield Partners LLC Acquires New Holdings in Medtronic PLC $MDT

WealthShield Partners LLC bought a new position in shares of Medtronic PLC (NYSE:MDT) during the 1st quarter, HoldingsChannel reports. The institutional investor bought 16,053 shares of the medical technology company’s stock, valued at approximately $1,391,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Curbstone Financial Management Corp raised its stake in shares of Medtronic by 1.8% during the fourth quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company’s stock valued at $537,000 after acquiring an additional 100 shares during the last quarter. New England Capital Financial Advisors LLC grew its stake in shares of Medtronic by 7.8% in the fourth quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company’s stock worth $135,000 after purchasing an additional 101 shares during the last quarter. Ipsen Advisor Group LLC lifted its holdings in Medtronic by 1.7% during the 4th quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock worth $572,000 after buying an additional 101 shares during the period. Quadrant Capital Group LLC grew its position in shares of Medtronic by 0.3% in the 4th quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock valued at $3,120,000 after buying an additional 101 shares during the last quarter. Finally, Baker Tilly Wealth Management LLC grew its position in shares of Medtronic by 3.3% in the 4th quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company’s stock valued at $309,000 after buying an additional 102 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on MDT shares. Piper Sandler restated a “neutral” rating and set a $85.00 price objective on shares of Medtronic in a research report on Tuesday, June 16th. Royal Bank Of Canada reissued an “outperform” rating and set a $118.00 target price on shares of Medtronic in a research report on Thursday, June 4th. Needham & Company LLC reissued a “buy” rating and set a $101.00 target price on shares of Medtronic in a research report on Wednesday, June 17th. Wells Fargo & Company lowered their price target on shares of Medtronic from $114.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, June 4th. Finally, Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Seventeen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $98.17.

Insider Activity

In other news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the sale, the executive vice president owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This trade represents a 10.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.26% of the company’s stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: TD Cowen cut its price target on Medtronic to $100 from $119 but kept a buy rating, signaling the stock still has meaningful upside from current levels. TD Cowen lowers price target on Medtronic
• Positive Sentiment: Another recent bullish note said Medtronic’s guidance is conservative and “built to be beaten,” highlighting strong fiscal 2026 revenue growth and potential upside catalysts from the MiniMed separation, tariff refunds, and payment relief. Medtronic guidance built to be beaten
• Positive Sentiment: Another Seeking Alpha article argued Medtronic is undervalued and that tailwinds are just beginning, reinforcing the idea that investors may be underappreciating the company’s growth potential. Medtronic undervalued and tailwinds just getting started
• Positive Sentiment: Citi also reportedly initiated or reiterated a buy view on Medtronic, adding to the wave of favorable analyst sentiment. Medtronic receives a buy from Citi
• Neutral Sentiment: Medtronic disclosed a voluntary global recall of its Octopus 4 Tissue Stabilizer after an assembly issue affecting 590 units. The issue appears limited, but recalls can create short-term investor caution. Medtronic recalls Octopus 4 Tissue Stabilizer
• Neutral Sentiment: Separate valuation pieces on Medtronic suggest the stock remains cheap relative to fundamentals, but these are more interpretation than hard catalysts for the share price. Medtronic stock could be undervalued

Medtronic Trading Up 1.7%

Shares of MDT stock traded up $1.39 during mid-day trading on Friday, hitting $83.78. The company’s stock had a trading volume of 7,190,992 shares, compared to its average volume of 8,643,010. The company has a market cap of $107.24 billion, a PE ratio of 22.46, a P/E/G ratio of 2.25 and a beta of 0.56. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. The company’s fifty day simple moving average is $79.11 and its 200-day simple moving average is $88.53. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last announced its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. During the same quarter in the prior year, the company earned $1.62 EPS. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, equities research analysts expect that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date is Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio (DPR) is currently 77.21%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).